Overview

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Status:
Terminated

Trial end date:
2020-12-22

Target enrollment:

Participant gender:

Summary

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe AD.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Collaborator:

AstraZeneca